Ken Arimura, Kenzo Hiroshima, Yoji Nagashima, Tadao Nakazawa, Akira Ogihara, Mami Orimo, Yasuto Sato, Hideki Katsura, Masato Kanzaki, Mitsuko Kondo, et al. LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study. BMC cancer. 2023. 23. 1. 1206-1206
Hiroki Ishihara, Takashi Ikeda, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Yoji Nagashima, Tsunenori Kondo, Toshio Takagi. Renal cell carcinoma outcomes in end-stage renal disease: A 40-year study from two Japanese institutions. International journal of urology : official journal of the Japanese Urological Association. 2023
Takahiro Osawa, Yasuhisa Fujii, Go Kimura, Hiroshi Kitamura, Yoji Nagashima, Sakura Iizumi, Tsuyoshi Osaka, Ryoichi Tsubouchi, Nobuo Shinohara. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care). BMJ open. 2023. 13. 7. e070275